| Date | Time | Source | |
| 05/21/2013 | 10:45AM | MWUS | Positive Patient Outcomes at One Year With Edwards Sapien XT Transcatheter Valve
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that one-year data from its European post-approval study of the Edwards SAPIEN XT transcatheter aortic heart valve continued to demonstrate positive patient outcomes, including all-cause... More...>> |
| 05/14/2013 | 9:15AM | MWUS | Edwards Lifesciences Announces CFO Retirement
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Thomas M. Abate, the company's chief financial officer, plans to retire later this year. Abate, who turns 60 in August, plans to remain CFO until his successor is in place. The... More...>> |
| 05/14/2013 | 9:15AM | MWUS | Edwards Lifesciences' Board Approves New $750 Million Share Repurchase Program
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that its Board of Directors has authorized a new share repurchase program to acquire up to an additional $750 million of the company's outstanding common shares. As of March 31, 2013... More...>> |
| 05/08/2013 | 7:07PM | MWUS | Edwards Lifesciences to Present at the Bank of America Merrill Lynch 2013 Healthcare Conference
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, is scheduled to present at the Bank of America Merrill Lynch 2013 Healthcare Conference at the Encore at the Wynn in Las Vegas, Nevada on Wednesday, May 15, 2013. Larry L. Wood, Edwards Lifesciences... More...>> |
| 05/07/2013 | 6:00PM | MWUS | Edwards Lifesciences to Webcast Annual Meeting of Stockholders
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, will host its Annual Meeting of Stockholders on Tuesday, May 14, 2013 beginning at 10:00 a.m. PT (1:00 pm ET) at its corporate headquarters in Irvine, California. A live webcast of the meeting will... More...>> |
| 04/24/2013 | 9:04AM | DJN | U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
Among the companies with shares expected to actively trade in Wednesday's session are Apple Inc. (AAPL), Edwards Lifesciences Corp. (EW) and VMware Inc. (VMW). In addition to raising its buyback program and increasing its dividend, Apple Inc. (AAPL) reported a mixed bag of fiscal second quarter results, notching its first... More...>> |
| 04/24/2013 | 6:47AM | DJN | U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
Among the companies with shares expected to actively trade in Wednesday's session are Edwards Lifesciences Corp. (EW), VMware Inc. (VMW) and Ethan Allen Interiors Inc. (ETH) Edwards Lifesciences reported disappointing sales of its flagship heart valves in the first quarter, leading the medical device firm to lower its... More...>> |
| 04/24/2013 | 5:30AM | ZACKS | Edwards Lags on Earnings & Rev - Analyst Blog
Edwards Lifesciences Corporation’s (EW) first-quarter 2013 adjusted earnings per share (EPS) came in at 72 cents, up 35.8% year over year, but lagging the Zacks Consensus Estimate of 76 cents. Adjusted EPS were also below the company-guided range of 74–78 cents. However, including a pre-tax gain of $83.6 million... More...>> |
| 04/23/2013 | 7:31PM | DJN | UPDATE: Edwards Lifesciences Reports Disappointing Sales, Outlook
--Edwards misses expectations as sales of its Sapien heart-valve stumble in the U.S. --Some customers are questioning the profitability and cost of the devices, Edwards says --Company lowers 2013 sales guidance range to between $2 billion and $2.1 billion (Updated throughout to add details and company comment.) By Joseph... More...>> |
| 04/23/2013 | 4:48PM | DJN | Edwards Lifesciences Reports Disappointing Sales, Lower Outlook
By Joseph Walker Edwards Lifesciences Corp. (EW) reported disappointing sales of its heart valves in the first quarter, leading the medical device firm to lower its full-year sales and earnings guidance. The Irvine, Calif., company's sales were hurt by lower-than-expected sales of its non-surgical Sapien heart valves and... More...>> |
| 04/23/2013 | 4:01PM | MWUS | Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended March 31, 2013, of $144.9 million compared to net income for the same period last year of $65.1 million. Earnings per diluted share for the same periods... More...>> |
| 04/17/2013 | 10:00AM | MWUS | Edwards Lifesciences to Host Earnings Conference Call on April 23, 2013
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, plans to announce its operating results for the quarter ended March 31, 2013 after the market closes on Tuesday, April 23, 2013 and will host a conference call at 5:00 p.m. ET that day to discuss its... More...>> |
| 04/03/2013 | 9:50AM | ZACKS | FDA Clears Affinity, Boosts MDT's Biz - Analyst Blog
The recent US Food and Drug Administration (“FDA”) 510(k) clearance for Affinity Fusion oxygenation system has enhanced the structural heart business of medical devices major – Medtronic, Inc. (MDT). The company also announced the first US clinical use of this new oxygenation system. Notably, last September... More...>> |
| 03/25/2013 | 10:54AM | PRNUS | Patient Advocate Foundation Launches the Heart Valve CareLine, Providing Individualized Assistance to Patients Experiencing C...
Patient Advocate Foundation Launches the Heart Valve CareLine, Providing Individualized Assistance to Patients Experiencing Challenges Accessing Healthcare PR Newswire HAMPTON, Va., March 25, 2013 The Heart Valve CareLine is now available toll-free to provide one-on-one case management support for patients diagnosed with... More...>> |
| 03/22/2013 | 2:10PM | ZACKS | Hanger Stays Neutral - Analyst Blog
On Mar 21, we retained Hanger Inc. (HGR) at Neutral, following its solid fourth-quarter 2012 results. In spite of the upbeat performance, we remain on the sidelines given the uncertain healthcare environment. Why the Retention? On Feb 13, Hanger’s adjusted earnings of 58 cents per share for the fourth quarter of... More...>> |
| 03/22/2013 | 11:50AM | ZACKS | Still Neutral on Omnicell - Analyst Blog
On Mar 19, 2013, we reiterated our Neutral recommendation on Omnicell Inc (OMCL) following its fourth-quarter results. The stock also carries a Zacks Rank #3 (Hold). Why the Reiteration? On Jan 31, 2013, Omnicell’s fourth-quarter EPS shot up 50% on a year-over-year basis to 18 cents, a beat of 12.5% over the Zacks... More...>> |
| 03/22/2013 | 8:40AM | ZACKS | Merge introduces Merge OrthoPACS - Analyst Blog
After a disappointing quarter, Merge Healthcare Incorporated (MRGE) has witnessed events that favor the company. This series of good news has been encouraging for investors. Recently, this imaging and interoperability solutions provider revealed encouraging data showing that its OrthoPACS have been used or is being... More...>> |
| 03/21/2013 | 9:31AM | PRNUS | Critical Alerts For Las Vegas Sands, Amgen, Edwards Lifesciences, Valeant Pharmaceuticals, and China Mobile Released By Inves...
Critical Alerts For Las Vegas Sands, Amgen, Edwards Lifesciences, Valeant Pharmaceuticals, and China Mobile Released By InvestorsObserver PR Newswire CHICAGO, March 21, 2013 CHICAGO, March 21, 2013 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LVS, AMGN, EW, VRX, and CHL. (Photo: http://photos.prnewswire.com/prnh/20120712/CG39046... More...>> |
| 03/20/2013 | 1:42PM | ZACKS | Positive Data for St Jude's Trifecta - Analyst Blog
Medical devices major – St. Jude Medical (STJ) made an online release of a new study about its Trifecta pericardial aortic stented tissue valve in The Journal of Thoracic and Cardiovascular Surgery. The device is used as a replacement for the damaged or malfunctioning aortic heart valve, which controls blood flow... More...>> |
| 03/19/2013 | 9:30AM | ZACKS | Pediatric Exclusivity for Hospira's Drug - Analyst Blog
Hospira, Inc. (HSP) recently gained pediatric exclusivity from the US Food and Drug Administration (FDA) for its injectable sedation drug, Precedex (dexmedetomidine HCl). The FDA’s decision resulted in a six-month extension of the period, during which Precedex’s generic may not be cleared following its patent... More...>> |
